Publications

• Brain-derived neurotrophic factor val66met genotype and early life stress effects upon bipolar course. Miller S, Hallmayer J, Wang PW, Hill SJ, Johnson SL, Ketter TA. J Psychiatr Res. 2013; 47 (2): 252-8
• Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder. Miller S, Ittasakul P, Wang PW, Hill SJ, Childers ME, Rasgon N, Ketter TA. J Clin Psychopharmacol. 2012; 32 (6): 814-9
• Pilot study of the efficacy of double-blind, placebo-controlled one-week olanzapine stabilization therapy in heterogeneous symptomatic bipolar disorder patients. Srivastava S, Wang PW, Hill SJ, Childers ME, Keller KL, Ketter TA. J Psychiatr Res. 2012; 46 (7): 920-6
• Gender-specific lipid profiles in patients with bipolar disorder. Vemuri M, Kenna HA, Wang PW, Ketter TA, Rasgon NL. J Psychiatr Res. 2011; 45 (8): 1036-41
• Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients. Wang PW, Hill SJ, Childers ME, Chandler RA, Rasgon NL, Ketter TA. J Psychiatr Res. 2011; 45 (8): 1128-32
• Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Ketter TA, Citrome L, Wang PW, Culver JL, Srivastava S. Acta Psychiatr Scand. 2011; 123 (3): 175-89